Drug Trial Radar · NCT00002548
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Last checked: Nov 20, 2026Latest source record: Mar 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
899
Actual
Start
Jan 1994
Primary completion
Oct 2003
Study completion Nov 2006
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group
- First posted
- Aug 11, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of melphalan, total-body irradiation, and peripheral stem cell transplantation with that of combination chemotherapy in treating patients who have previously untreated multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
recombinant interferon alfaBiological
3 million units/m2 SQ Monday-Wednesday -Friday (3 times a week)
carmustineDrug
20 mg/m2 I.V. day 1 q 35 days
cyclophosphamideDrug
1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
dexamethasoneDrug
40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
doxorubicin hydrochlorideDrug
10 mg/m2/day continuous 1 - 4 q 5 weeks
melphalanDrug
140 mg/m2 is given IV within 30 minutes of constitution on Day -5
prednisoneDrug
40 mg/m2 PO days 1-7 q 35 days
vincristine sulfateDrug
0.5 mg/day continuous 1 - 4 q 5 weeks
allogeneic bone marrow transplantationProcedure
day 0
autologous bone marrow transplantationProcedure
day 0
peripheral blood stem cell transplantationProcedure
day 0
radiation therapyRadiation
administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
Primary outcomes
What the sponsor says the trial is designed to measure.
- survivalTime frame: 3 years from randomization
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona
CCOP - Colorado Cancer Research Program, Inc.
Denver, Colorado
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois
CCOP - Evanston
Evanston, Illinois
CCOP - Illinois Oncology Research Association
Peoria, Illinois
CCOP - Carle Cancer Center
Urbana, Illinois
Indiana University Cancer Center
Indianapolis, Indiana
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana
CCOP - Iowa Oncology Research Association
Des Moines, Iowa
CCOP - Ochsner
New Orleans, Louisiana
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
New England Medical Center Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
CCOP - Ann Arbor Regional
Ann Arbor, Michigan
CCOP - Kalamazoo
Kalamazoo, Michigan
CCOP - Duluth
Duluth, Minnesota
University of Minnesota Cancer Center
Minneapolis, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota
Veterans Affairs Medical Center - New York
New York, New York
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York
University of Rochester Cancer Center
Rochester, New York
Albert Einstein Comprehensive Cancer Center
The Bronx, New York
Ireland Cancer Center
Cleveland, Ohio
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania
Hahnemann University Hospital
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
CCOP - Marshfield Medical Research and Education Foundation
Marshfield, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.